Wednesday, June 10, 2026

pharma Β· Acute Myeloid Leukemia Β· Relapsed and/or refractory Acute Myeloid Leukemia Β· KURA

Kura Oncology

Kura Oncology clinical programs β€” 25 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

12730 High Bluff Dr, Suite 400, San Diego, California 92130, US HQ
2014 Founded
313 Employees
Public company Type
KURA Β· NYSE Ticker
Company details
Status
Public
HQ
12730 High Bluff Dr, Suite 400, San Diego, California 92130, US
Founded
2014
Employees
313
Programs
25
Drugs
14
Patents
132
Intelligence Β· Clinical Programs

Kura Oncology projects

25 ClinicalTrials.gov programs sponsored by Kura Oncology.

Kura Oncology has 25 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. KO-MEN-017

    Kura Oncology

    NPM1-m and KMT2A-r Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  2. Ziftomenib

    Kura Oncology

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial
  3. Cytarabine

    Kura Oncology

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial
  4. Dexamethasone

    Kura Oncology

    Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial
  5. Tipifarnib

    Kura Oncology

    HNSCC

    phase 2 small molecule completed

    1 trial
  6. Tipifarnib

    Kura Oncology

    Relapsed or Refractory Peripheral T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial
  7. Tipifarnib

    Kura Oncology

    HRAS Gene Mutation

    phase 2 small molecule completed

    1 trial
  8. Tipifarnib

    Kura Oncology

    Leukemia, Myelomonocytic, Chronic

    phase 2 small molecule completed

    1 trial
  9. Tipifarnib

    Kura Oncology

    Myelodysplastic Syndromes

    phase 2 small molecule terminated

    1 trial
  10. Tipifarnib

    Kura Oncology

    Thyroid Cancer

    phase 2 small molecule completed

    1 trial
  11. Ziftomenib

    Kura Oncology

    Advanced Malignant Neoplasm

    phase 2 small molecule active

    1 trial
  12. Ziftomenib, Ziftomenib

    Kura Oncology

    Relapsed and/or refractory Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial
  13. Darlifarnib

    Kura Oncology

    Solid Tumors With HRAS Alterations

    phase 1 small molecule active

    1 trial
  14. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    Kura Oncology

    Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma

    phase 1 other active

    1 trial
  15. KO-947

    Kura Oncology

    Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial
  16. KO-MEN-008

    Kura Oncology

    Relapsed and/or refractory Acute Myeloid Leukemia

    phase 1 other active

    1 trial
  17. Tipifarnib

    Kura Oncology

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial
  18. Tipifarnib

    Kura Oncology

    NSCLC

    phase 1 small molecule terminated

    1 trial
  19. Venetoclax

    Kura Oncology

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial
  20. Ziftomenib

    Kura Oncology

    AML

    phase 1 small molecule active

    1 trial
  21. Ziftomenib

    Kura Oncology

    KMT2A-rearranged

    phase 1 small molecule active

    1 trial
  22. Ziftomenib

    Kura Oncology

    Refractory Acute Leukemia

    phase 1 small molecule active

    1 trial
  23. Ziftomenib

    Kura Oncology

    Relapsed/Refractory KMT2A-r Acute Leukemia

    phase 1 small molecule active

    1 trial
  24. Ziftomenib

    Kura Oncology

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial
  25. ziftomenib

    Kura Oncology

    Gastrointestinal Stromal Tumor (GIST)

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Kura Oncology have?

25 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.